Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TEE-2555
- Development stage
- Preclinical
- Lead developer
- Apteeus
- Modality
- Small Molecules
01
Overview
TEE-2555 is a repurposed small molecule drug candidate being developed by Apteeus for the treatment of peroxisomal disorders, specifically PEX deficiency (peroxisomopathy). Identified through a phenotypic screening assay using patient-derived primary cells, TEE-2555 is designed to rescue peroxisome biogenesis defects. Peroxisomal disorders are caused by mutations in PEX genes, which encode peroxins necessary for peroxisome assembly and maintenance. TEE-2555 aims to restore these processes, potentially addressing the underlying metabolic and developmental issues associated with these rare congenital disorders. It is currently in the preclinical stage of development and was identified from a screen of over 2,500 existing drugs.
Beyond the preview
Go deeper on TEE-2555.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TEE-2555.